Breast International Group

• NCT05128773

  Collaborator, Phase 3, Terminated, 3 people, 22 Nov 2021

• Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)

  Collaborator, Phase 3, Terminated, 27 people, 1 Oct 2021

• NCT03609047

  Collaborator, Phase 2, Active, not recruiting, 366 people, 1 Aug 2018

• NCT03498716

  Collaborator, Phase 3, Terminated, 2,199 people, 17 Apr 2018

• NCT02536742

  Collaborator, Phase 2, Completed, 124 people, 1 Sept 2015

• NCT02513394

  Collaborator, Phase 3, Active, not recruiting, 5,796 people, 31 Jul 2015

• NCT02273973

  Collaborator, Phase 2, Completed, 334 people, 24 Oct 2014

• NCT01864746

  Collaborator, Phase 3, Completed, 1,250 people, 30 May 2013

• NCT01358877

  Collaborator, Phase 3, Completed, 4,804 people, 24 May 2011

• NCT00553410

  Collaborator, Phase 3, Completed, 4,884 people, 5 Nov 2007

• NCT00553358

  Collaborator, Phase 3, Completed, 455 people, 5 Nov 2007

• NCT00433589

  Collaborator, Phase 3, Completed, 6,600 people, 12 Feb 2007

• NCT00066807

  Collaborator, Phase 3, Terminated, 29 people, 7 Aug 2003

• NCT00066703

  Collaborator, Phase 3, Completed, 2,672 people, 7 Aug 2003

• NCT00066690

  Collaborator, Phase 3, Completed, 3,066 people, 7 Aug 2003

• NCT00010153

  Collaborator, Phase 3, Terminated, 27 Jan 2003

Sources: clinicaltrials.gov